04X Stock Overview Develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Personalis, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Personalis Historical stock prices Current Share Price US$5.81 52 Week High US$6.86 52 Week Low US$0.94 Beta 1.86 1 Month Change 84.44% 3 Month Change 7.89% 1 Year Change 334.88% 3 Year Change -55.00% 5 Year Change n/a Change since IPO -69.74%
Recent News & Updates Personalis, Inc. announced that it expects to receive $49.999997 million in funding from Merck Sharp & Dohme LLC Dec 20
Third quarter 2024 earnings released: US$0.64 loss per share (vs US$0.60 loss in 3Q 2023) Nov 08 Personalis, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024
President recently sold €131k worth of stock Nov 06
Personalis, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 24 Personalis, Inc. announced that it expects to receive $17.745 million in funding from Tempus AI, Inc Aug 16
See more updates Personalis, Inc. announced that it expects to receive $49.999997 million in funding from Merck Sharp & Dohme LLC Dec 20
Third quarter 2024 earnings released: US$0.64 loss per share (vs US$0.60 loss in 3Q 2023) Nov 08 Personalis, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024
President recently sold €131k worth of stock Nov 06
Personalis, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 24 Personalis, Inc. announced that it expects to receive $17.745 million in funding from Tempus AI, Inc Aug 16
Second quarter 2024 earnings released: US$0.24 loss per share (vs US$0.50 loss in 2Q 2023) Aug 08
Personalis, Inc. Revises Earnings Guidance for the Year 2024 Aug 08
Personalis, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Jul 25 Personalis, Inc. Revises Earnings Guidance for the Full Year of 2024
First quarter 2024 earnings released: US$0.26 loss per share (vs US$0.61 loss in 1Q 2023) May 09
Personalis, Inc. to Report Q1, 2024 Results on May 08, 2024 Apr 26
Personalis, Inc., Annual General Meeting, May 17, 2024 Apr 03
Personalis, Inc. Announces Publication Validating Next Personal Test for Ultra-Sensitive MRD Detection and Cancer Treatment Response Monitoring Mar 26
Full year 2023 earnings released: US$2.25 loss per share (vs US$2.48 loss in FY 2022) Mar 01
Personalis, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024 Mar 01
Personalis, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 15
Personalis Announces Medicare Coverage for Next Dx(R) Comprehensive Genomic Tumor Profiling Assay Jan 16
Personalis, Inc. Provides Unaudited Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023 Jan 05 Personalis, Inc. has filed a Follow-on Equity Offering in the amount of $50 million. Dec 22
Third quarter 2023 earnings released: US$0.60 loss per share (vs US$0.58 loss in 3Q 2022) Nov 09 Personalis, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023
Personalis, Inc. Launches NeXT Personal DX for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer Oct 27
Personalis, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 25
Personalis, Inc. Announces the Presentation of Initial Findings from Its Work with the Tracerx Lung Cancer Study Oct 22
Personalis, Inc. Appoints Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance Oct 20
New minor risk - Shareholder dilution Aug 13
Personalis, Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2023 Aug 10
Second quarter 2023 earnings released: US$0.50 loss per share (vs US$0.60 loss in 2Q 2022) Aug 09
Personalis, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 26
Personalis, Inc. Announces Board Changes Jun 14
High number of new directors May 23
First quarter 2023 earnings released: US$0.61 loss per share (vs US$0.63 loss in 1Q 2022) May 05
Personalis, Inc. Provides Earnings Guidance for the Full Year 2023 May 05
Full year 2022 earnings released: US$2.48 loss per share (vs US$1.49 loss in FY 2021) Feb 26
Personalis, Inc. to Report Q4, 2022 Results on Feb 23, 2023 Feb 10 Personalis, Inc. Provides Revenue Guidance for the Fourth Quarter Ended December 31, 2022 Personalis, Inc. Announces Retirement of John West from the Board of Directors
Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.40 loss in 3Q 2021) Nov 04
Personalis, Inc. Provides Earnings Guidance for the Full Year of 2022 Nov 03
Personalis, Inc. Appoints Christopher Hall as SVP and Head, Diagnostics Business Nov 01
Personalis, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 20
Second quarter 2022 earnings released: US$0.60 loss per share (vs US$0.34 loss in 2Q 2021) Aug 05 Personalis, Inc. Provides Earnings Guidance for the Year 2022
Personalis, Inc. to Report Q2, 2022 Results on Aug 03, 2022 Jul 21 Personalis, Inc.(NasdaqGM:PSNL) dropped from Russell 2000 Growth Index
First quarter 2022 earnings released: US$0.63 loss per share (vs US$0.29 loss in 1Q 2021) May 06
Personalis, Inc. Provides Earnings Guidance for the Full Year of 2022 May 05
High number of new directors Apr 27
Personalis, Inc. to Report Q1, 2022 Results on May 04, 2022 Apr 21
Personalis Announces Issuance of Additional US Patent Related to the Next Personal Platform Apr 13
Personalis, Inc., Annual General Meeting, May 17, 2022 Apr 02
High number of new directors Mar 11
No longer forecast to breakeven Feb 26
Personalis, Inc. Provides Earnings Guidance for the Full Year 2022 Feb 25
Forecast to breakeven in 2024 Feb 12
Personalis, Inc. to Report Q4, 2021 Results on Feb 24, 2022 Feb 11
Personalis, Inc. Provides Unaudited Preliminary Revenue Guidance for the Fourth Quarter and Full Year of 2021 Jan 07
Personalis Launches NeXT Personal™, A Tumor-Informed Liquid Biopsy Assay for MRD and Recurrence Detection With Part-Per-Million Sensitivity Dec 17
Third quarter 2021 earnings released: US$0.40 loss per share (vs US$0.27 loss in 3Q 2020) Nov 05
Senior VP & CFO recently sold €57k worth of stock Sep 23
Chief Financial Officer recently sold €71k worth of stock Sep 10
Second quarter 2021 earnings released: US$0.34 loss per share (vs US$0.29 loss in 2Q 2020) Aug 06
Chief Financial Officer recently sold €51k worth of stock Jun 10
Independent Director has left the company May 20
Personalis, Inc. Provides Financial Guidance for the Second Quarter and Full Year of 2021 May 07
First quarter 2021 earnings released: US$0.29 loss per share (vs US$0.29 loss in 1Q 2020) May 06
Chief Financial Officer recently sold €55k worth of stock Mar 23
Personalis, Inc. Announces Board Changes Mar 11
Chief Financial Officer recently sold €82k worth of stock Mar 10
Independent Director has left the company Mar 09
New 90-day low: €22.00 Mar 05
Revenue beats expectations Feb 27
Full year 2020 earnings released: US$1.20 loss per share (vs US$1.39 loss in FY 2019) Feb 27
Natera, Inc. and Personalis, Inc. Partner for Personalized Monitoring in Oncology Feb 18
Personalis, Inc. Announces Appointment of Susan Moriconi as VP of People and Chief Human Resources Officer Feb 09 Shareholder Returns 04X DE Life Sciences DE Market 7D 73.7% -2.8% -2.6% 1Y 334.9% -5.9% 6.9%
See full shareholder returns
Return vs Market: 04X exceeded the German Market which returned 6.9% over the past year.
Price Volatility Is 04X's price volatile compared to industry and market? 04X volatility 04X Average Weekly Movement 24.3% Life Sciences Industry Average Movement 7.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 04X's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 04X's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample.
Show more Personalis, Inc. Fundamentals Summary How do Personalis's earnings and revenue compare to its market cap? 04X fundamental statistics Market cap €389.33m Earnings (TTM ) -€87.64m Revenue (TTM ) €83.85m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 04X income statement (TTM ) Revenue US$87.49m Cost of Revenue US$60.01m Gross Profit US$27.48m Other Expenses US$118.92m Earnings -US$91.44m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.29 Gross Margin 31.41% Net Profit Margin -104.52% Debt/Equity Ratio 1.0%
How did 04X perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 10:29 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Personalis, Inc. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Derik de Bruin BofA Global Research Mark Massaro BTIG Patrick Donnelly Citigroup Inc
Show 10 more analysts 
